Dr. Abbey and Dr. Callanan Inducted into The Retina Society
Texas Retina’s Ashkan M. Abbey, MD, and retired Texas Retina physician David Callanan, MD, were officially inducted into The Retina Society at the organization’s 57th Annual Scientific Meeting held September 11-15, in
read moreInflammatory Eye Disease Awareness Week
Prevent Blindness has declared September 16–22, 2024, as Inflammatory Eye Disease Awareness Week. There are several inflammatory eye conditions. The one we specialize in at Texas Retina is called uveitis [u-vee-i-tis]. Understanding
read moreOffices Closed for Labor Day on 9/2/24
All Texas Retina Associates offices will be closed on Monday, September 2, 2024, in observance of Labor Day. We wish everyone a safe and happy holiday weekend!
read moreTexas Retina Honors Founder Dr. Vaiser with Donation to Retina Foundation
On behalf of the entire Texas Retina team, Gary Edd Fish, MD, recently presented a $2,000 donation to the Retina Foundation to honor the 90th birthday of one of Texas Retina’s founders,
read moreDr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for
read moreCan Ozempic Affect Your Eyes or Vision?
Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a
read moreDr. Wang Invited to Serve as Guest Lecturer at Ohio State University
Texas Retina’s Robert C. Wang will speak at The Ohio State University’s 7th Annual Retina Case Forum on Friday, August 16, 2024, as an invited guest lecturer. The event is a case-based
read moreRecent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma
The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated
read more